Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

329.91 +0.75 (+0.23%)
Streaming Delayed Price Updated: 10:51 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,611
Open 330.37
Bid (Size) 329.29 (4)
Ask (Size) 330.84 (4)
Prev. Close 329.16
Today's Range 325.54 - 331.81
52wk Range 208.62 - 339.56
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Arvinas Stock Earns 82 RS Rating
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
Don't overlook NASDAQ:UTHR—it's a hidden gem with strong fundamentals and an attractive price tag.
Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued. 
Via Chartmill

Performance

YTD
+45.11%
+45.11%
1 Month
+4.39%
+4.39%
3 Month
+40.95%
+40.95%
6 Month
+52.57%
+52.57%
1 Year
+34.26%
+34.26%

More News

Read More
Denali Therapeutics Stock Gets Technical Rating Upgrade
Via Investor's Business Daily
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today
Via Benzinga
3 Biotech Stocks to Buy Now: Q3 Edition
Via InvestorPlace
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
Unveiling 6 Analyst Insights On United Therapeutics
Via Benzinga
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
3 Undervalued Stocks on Track to Double (or More) by 2028
Via InvestorPlace
Members of Congress Buy and Sell Stocks. These ETFs Let You Invest Like Democrats or Republicans.
Via The Motley Fool
Topics ETFs
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Via InvestorPlace
Chart Of The Day: United Therapeutics - Drugs For Chronic Illnesses
Via Talk Markets
UroGen Pharma Stock Earns 91 RS Rating
Via Investor's Business Daily
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
When you look at NASDAQ:UTHR, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Arcellx Stock Earns Relative Strength Rating Upgrade
Via Investor's Business Daily
The 3 Best Medical Device Stocks to Buy in June 2024
Via InvestorPlace
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
Via Investor's Business Daily
Krystal Biotech Stock Sees RS Rating Jump To 91
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
Via Investor's Business Daily
For those who appreciate value investing, NASDAQ:UTHR is a compelling option with its solid fundamentals.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.